Komori
Disclosure4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding Borrowing of Funds

To fund working capital, research and development expenses and other needs, we raised a total of ¥515 million by borrowing ¥340 million from Representative Director and President Yoshida Fuminori (吉田 文紀) and ¥175 million from Yoshida Ikuko (吉田 いく子). Both loans carry annual interest of 0.0%, are unsecured and will be repaid in a lump sum on 30 December 2026.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
515000000
yen
Wording
Definitive
How definitive the wording is.

Decision and Details

Board of Directors

Borrowing of funds

Decision8 October 2026
Period CoveredFrom the borrowing execution date of 15 October 2026 to the repayment due date of 30 December 2026
Implementation15 October 2026 (completed)
Going forwardLump-sum repayment on the due date, 30 December 2026
AmountBorrowing from Yoshida Fuminori (吉田 文紀): ¥340 million; borrowing from Yoshida Ikuko (吉田 いく子): ¥175 million; total: ¥515 million
Quantity / scale2 loans
Reason

Funding for working capital, research and development expenses and other funds necessary to conduct our business

Impact on Business Performance

There will be no impact on consolidated results for the fiscal year ending December 2026.

Interest ratesAnnual interest of 0.0% on both loans
CollateralBoth loans are unsecured
Decision and Details
ItemDetails
Matter CoveredBorrowing of funds
Decision-Making BodyBoard of Directors
Decision Date8 October 2026
Implementation Date15 October 2026 (completed)
Period CoveredFrom the borrowing execution date of 15 October 2026 to the repayment due date of 30 December 2026
AmountBorrowing from Yoshida Fuminori (吉田 文紀): ¥340 million; borrowing from Yoshida Ikuko (吉田 いく子): ¥175 million; total: ¥515 million
Quantity / scale2 loans
Impact on Business PerformanceThere will be no impact on consolidated results for the fiscal year ending December 2026.
ReasonFunding for working capital, research and development expenses and other funds necessary to conduct our business
Future plansLump-sum repayment on the due date, 30 December 2026
Interest ratesAnnual interest of 0.0% on both loans
CollateralBoth loans are unsecured
Items this document does not state (2)
Governing RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To fund working capital, research and development expenses and other funds necessary to conduct our business.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Borrowing of Funds | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori